Eli Lilly and CompanyNYSE: LLY
Health Care · Pharmaceuticals
$1,099.89
-1.09%
Vol: 2.6M
Research Digest
Friday, June 19, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 18ARK Investment buys 41,000 LLY shares on June 17 as Retevmo Phase 3 trial shows 83% recurrence risk reduction, reinforcing Lilly's oncology pipeline strength.Positive▶
On June 17, 2026, ARK Investment Management acquired 41,000 shares of Eli Lilly, signaling renewed institutional confidence in the stock. The catalyst aligns with a landmark Phase 3 result for Retevmo (selpercatinib) in the LIBRETTO-432 trial, which showed an 83% reduction in disease recurrence or death versus placebo for early-stage RET fusion-positive non-small cell lung cancer. Lilly is the world's most valuable pharma company, with a market cap above $1 trillion, driven by its dominant GLP-1 obesity and diabetes franchise. The company had over $16.8 billion in 2025 operating cash flow, fueling aggressive M&A across neuroscience, oncology, and cardiometabolic health. The next earnings report is scheduled for August 5, 2026; the risk is that the premium valuation (P/E ~40x) leaves little room for pipeline disappointments.
Jun 17Eli Lilly's Jaypirca cut risk of CLL progression or death by 45% in a landmark Phase 3 trial, broadening its oncology story.Positive▶
On June 14, 2026, at the EHA congress, Lilly reported Phase 3 BRUIN CLL-322 results showing Jaypirca (pirtobrutinib) plus venetoclax and rituximab reduced the risk of disease progression or death by 45% versus venetoclax/rituximab alone in 639 previously treated CLL/SLL patients, with 86.9% progression-free at two years versus 71.8%. It is the first Phase 3 study to show superiority over a venetoclax-containing control arm in CLL, supporting potential label expansion and diversification beyond Lilly's obesity franchise. Barclays reiterated a Buy rating on June 15. The catalyst adds to a strong early-June run that included retatrutide late-stage obesity data and an FDA-approved less-frequent Ebglyss regimen. The bear case: shares trade near a 41x P/E versus ~15x for the broader US pharma industry, pricing in heavy growth expectations, and reports of some employers dropping weight-loss drug coverage pressured the stock about 1% on June 12. Execution and reimbursement risk around the GLP-1 franchise remain the key overhang despite the oncology win.
Jun 16Eli Lilly hits record high on June 15 after strong late-stage obesity data for retatrutide and oral GLP-1 orforglipronPositive▶
Eli Lilly shares reached a record high of about $1,149 on Monday, June 15, 2026, propelled by a flurry of early-June clinical catalysts. Late-stage data for its triple-hormone obesity agent retatrutide (targeting GIP, GLP-1 and glucagon) and progress for its oral GLP-1 orforglipron (branded Foundayo) underpinned the move, alongside an FDA-approved less-frequent dosing regimen for dermatology drug Ebglyss. The clinical momentum reinforces Lilly's dominant GLP-1 franchise anchored by Mounjaro and Zepbound and feeds strong share-price momentum, with a 30-day return around 17%. A near-term headwind emerged on reports that some employers plan to drop weight-loss-drug coverage, which could pressure GLP-1 volume growth. Valuation is also a risk, with the stock trading near 41x earnings versus roughly 15x for the U.S. pharma industry.
Jun 15Eli Lilly's Jaypirca cut risk of CLL/SLL progression or death by 45% in Phase 3 BRUIN CLL-322 trial reported June 14, but shares slipped ~2.4%.Mixed▶
On June 14, 2026, Eli Lilly announced results from the Phase 3 BRUIN CLL-322 trial of Jaypirca (pirtobrutinib), a non-covalent BTK inhibitor, in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). Adding Jaypirca to a venetoclax-based time-limited regimen reduced the risk of disease progression or death by 45% versus standard venetoclax plus rituximab. The data strengthen Lilly's oncology franchise beyond its dominant GLP-1/obesity portfolio. The key risk is that an overall survival benefit has not yet been demonstrated, with the OS hazard ratio at 0.89 and the analysis still immature. Despite the positive readout, LLY fell about 2.41% on June 14 amid mixed large-cap pharma trading and lingering concern over reports that some employers plan to drop weight-loss drug coverage. The stock had recently hit record highs near $1,149 on obesity/diabetes pipeline momentum.
Jun 14Eli Lilly slips ~1% as some employers move to drop weight-loss drug coverage, even as early-June obesity pipeline catalysts keep momentum strong.Mixed▶
On June 12 LLY shares fell about 1% on reports that some employers plan to discontinue coverage of GLP-1 weight-loss drugs, a demand-side risk for Lilly's key obesity franchise. The pullback came against a backdrop of strong early-June catalysts, including positive late-stage Phase 3 data for obesity drug retatrutide, progress on oral GLP-1 candidates, and an FDA-approved less-frequent Ebglyss maintenance regimen. The stock has posted a roughly 17% 30-day return on this flow of clinical and regulatory news. Why it matters: employer coverage decisions could pressure US obesity-drug volumes even as the pipeline strengthens. The main risk is reimbursement headwinds narrowing the addressable market despite clinical wins. Analysts broadly maintain positive outlooks on Lilly.
May 21Isomorphic Labs expands AlphaFold 3 drug-discovery partnership with Lilly May 21; LLY also closes $202M Engage Biologics acquisition and $6.5B bond offeringPositive▶
On May 21, 2026, Alphabet's Isomorphic Labs announced expansion of its AI drug-discovery partnership with Eli Lilly using AlphaFold 3 to identify novel therapeutic targets for complex diseases. On May 20, Lilly announced acquiring Engage Biologics for up to $202M cash, its seventh acquisition of 2026, gaining the Tethosome non-viral DNA delivery platform. Lilly also priced $6.5B of bonds ($750M Floating Rate Notes due 2028-2029 plus $5.75B fixed-rate notes through 2066). Shares rose ~1% to their highest level since March 2. Analysts raised rolling 12-month EPS estimates by 24%. Retatrutide trial data expected at June ADA Scientific Sessions.
May 20Eli Lilly stock closes near $1,005 as Q1 revenue surges 56% on Mounjaro/Zepbound strength and additional $4.5B Indiana manufacturing investment.Positive▶
Eli Lilly shares closed around $1,005.20 on May 15, 2026 after the company reported Q1 2026 revenue of $19.8B, beating estimates of $17.6B, driven by 125% growth in Mounjaro to $8.6B and 80% growth in Zepbound to $4.1B. The company raised full-year guidance and announced an additional $4.5B investment in Indiana manufacturing, bringing total commitments since 2020 above $21B. The FDA approval of Foundayo, the only approved GLP-1 pill that can be taken anytime without food/water restrictions, materially expands the addressable patient population. Lilly will appear at Bernstein's Strategic Decisions Conference on May 28. The risk is heavy reliance on the GLP-1 franchise as competition from oral and next-gen incretins intensifies. Analyst consensus is Buy with a 12-month target of $1,210.
May 19Eli Lilly raised full-year 2026 revenue guidance to $82-85B and announced a $4.5B Indiana manufacturing expansion to meet surging GLP-1 demand.Positive▶
Eli Lilly committed an additional $4.5 billion across Indiana manufacturing sites in May 2026, bringing total Indiana capital outlay to $21 billion since 2020 to meet booming demand for Mounjaro, Zepbound and the new oral pill Foundayo. The company raised its 2026 revenue forecast to $82-85 billion after Q1 revenue grew 56% to $19.8 billion, with GLP-1 products generating $12.8 billion combined. The board declared a Q2 dividend of $1.73 per share, and the company opened its first dedicated genetic medicine facility. Barclays reaffirmed Buy on May 14. Bear case: investor expectations are extraordinarily high, capacity build-out risks oversupply if GLP-1 competition intensifies, and execution on Foundayo ramp is critical.
May 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 15Eli Lilly raises 2026 revenue guidance to $82-85B after Q1 beat driven by Mounjaro and Zepbound surgePositive▶
Lilly reported Q1 2026 revenue of $19.8B (up 56% YoY), beating consensus of $17.6B and driving shares up 9.8%. Mounjaro revenue rose 125% to $8.6B and Zepbound rose 80% to $4.1B. The company raised full-year revenue guidance by $2B to $82-85B and lifted EPS guidance. Lilly also announced a $4.5B additional investment in its Lebanon, Indiana manufacturing site, bringing total Indiana capex to $21B since 2020. The board declared a Q2 dividend of $1.73 per share. New Foundayo (orforglipron) trial data showed significant weight loss in adults 65+, expanding the GLP-1 pill's addressable population.
May 14Eli Lilly reports May 13 that oral GLP-1 orforglipron sustains weight loss in patients transitioning off injectable GLP-1s, de-risking its pivotal oral obesity franchise.Positive▶
On May 13, 2026, Eli Lilly disclosed clinical data showing patients who stopped injectable GLP-1 therapy maintained most of their weight loss and metabolic benefits while transitioning to daily oral orforglipron. The data addresses the largest commercial overhang for GLP-1 drugs — weight regain after discontinuation — and supports a more convenient oral pathway. Earlier in May, Lilly raised FY26 guidance to $82-85B revenue and $35.50-$37.00 EPS following Q1 revenue of $19.8B (vs $17.6B consensus), driven by $12.8B combined Mounjaro/Zepbound sales. Lilly also committed an additional $4.5B to Indiana manufacturing (>$21B total since 2020). Risk: 24/7 Wall St noted pricing pressure overhang heading into May, and the stock is entering a seasonally weak period after a strong run.
May 13Eli Lilly Q1 revenue surged 56% to $19.8B on Mounjaro and Zepbound; FDA approved oral GLP-1 pill Foundayo and Lilly raised full-year guidance to $82-85B with an additional $4.5B Lebanon, Indiana manufacturing investment.Positive▶
Eli Lilly reported Q1 2026 revenue of $19.8B, up 56% YoY, beating the $17.6B consensus, driven by Mounjaro revenue up 125% to $8.6B and Zepbound up 80% to $4.1B (combined $12.8B). The FDA approved Foundayo (orforglipron), the only approved GLP-1 pill that can be taken any time of day without food/water restrictions. Lilly raised full-year 2026 revenue guidance to $82-85B. On May 6, the company opened Lilly Lebanon Advanced Therapies and announced an additional $4.5B Lebanon investment, bringing planned capital at that site to $18B+ and total Indiana capex to $21B since 2020. Shares jumped 2.4% on May 12 on the manufacturing news and another 4.36% on May 11. The FDA also proposed a rule to prohibit compounding of copycat versions. May 10 marked Lilly's 150th anniversary.
May 12Eli Lilly Q1 revenue surged 56% to $19.8B on Mounjaro/Zepbound strength, EPS of $8.55 beat $6.66 consensus, prompting a 13% rally and raised FY26 guidance to $82-85B revenue and $35.50-37.00 EPS.Positive▶
Lilly reported blowout Q1 2026 results with Mounjaro sales up 125% to $8.66B and Zepbound up 80% to $4.16B. The FDA approved Foundayo, Lilly's first once-daily GLP-1 pill that can be taken without food or water restrictions, materially expanding the addressable market. The company committed an additional $4.5B for Indiana manufacturing, including the new Lebanon Advanced Therapies facility (its first dedicated genetic medicine site), bringing total Indiana capex to over $21B since 2020. The stock posted a 9.8% post-earnings bull gap and traded around $994. Risk: regulatory scrutiny of GLP-1 pricing remains an overhang.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| LLYELI | $1,099.89 | -1.09% | — | 27.3x | 0.51 | $1.08T |
| JNJJOHNSON | $228.45 | -2.46% | — | 20.7x | 0.23 | $633.2B |
| MRKMERCK | $114.08 | -1.18% | — | 13.5x | 0.20 | $320.0B |
| PFEPFIZER | $25.28 | -2.49% | — | 8.6x | 0.31 | $138.6B |
| BMYBRISTOL | $54.15 | -2.05% | — | 9.4x | 0.23 | $118.7B |
| ZTSZOETIS | $78.71 | +1.88% | — | 10.1x | 0.75 | $31.4B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.